Characteristics of the gouty patients who received probenecid (n = 20).
| Characteristics | Mean (95% CI) |
|---|---|
| Age, yrs | 59 (54–64) |
| Body mass index, kg/m2 | 27.6 (25.5–29.7) |
| Estimated creatinine clearance, ml/min* | 76.5 (65.5–87.6) |
| Plasma urate concentration at baseline taking allopurinol, mmol/l | 0.37 (0.34–0.41) |
| History of gout, n (%) | |
| Duration of gout < 10 yrs | 12 (60) |
| Presence of ≥ tophi | 5 (30) |
| No. acute attacks in past 2 yrs | |
| 0 | 4 (20) |
| 1–3 | 6 (30) |
| 4–5 | 3 (15) |
| > 5 | 7 (35) |
| Duration of allopurinol therapy < 5 yrs | 12 (60) |
| Concomitant medications at study entry, n (%) | |
| No regular medicines | 3 (17) |
| Aspirin 100 mg/day | 3 (17) |
| Diuretics** | 4 (22) |
| Warfarin | 2 (11) |
| Angiotensin II receptor antagonists (no losartan) | 3 (17) |
| ß-adrenergic receptor antagonists | 3 (17) |
| Angiotensin converting enzyme inhibitors | 4 (22) |
| Calcium channel blockers | 2 (11) |
| HMG-CoA reductase inhibitors | 7 (39) |